EI

252.9

+0.04%↑

SAN

81.58

+0.2%↑

SHL.DE

46.07

+0.11%↑

ARGX

554.4

-0.07%↓

PHIA

23.22

+0.96%↑

EI

252.9

+0.04%↑

SAN

81.58

+0.2%↑

SHL.DE

46.07

+0.11%↑

ARGX

554.4

-0.07%↓

PHIA

23.22

+0.96%↑

EI

252.9

+0.04%↑

SAN

81.58

+0.2%↑

SHL.DE

46.07

+0.11%↑

ARGX

554.4

-0.07%↓

PHIA

23.22

+0.96%↑

EI

252.9

+0.04%↑

SAN

81.58

+0.2%↑

SHL.DE

46.07

+0.11%↑

ARGX

554.4

-0.07%↓

PHIA

23.22

+0.96%↑

EI

252.9

+0.04%↑

SAN

81.58

+0.2%↑

SHL.DE

46.07

+0.11%↑

ARGX

554.4

-0.07%↓

PHIA

23.22

+0.96%↑

Search

Pharming Group NV

Avatud

0.957 -5.81

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.952

Max

1.018

Põhinäitajad

By Trading Economics

Sissetulek

19M

4.7M

Müük

14M

93M

Aktsiakasum

-0.02

Kasumimarginaal

5.035

Töötajad

404

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+69.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

81M

699M

Eelmine avamishind

6.77

Eelmine sulgemishind

0.957

Pharming Group NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2025, 17:49 UTC

Suurimad hinnamuutused turgudel

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. aug 2025, 17:18 UTC

Suurimad hinnamuutused turgudel

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. aug 2025, 16:25 UTC

Tulu

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement 2Q Rev $25.8M >EXOD

11. aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. aug 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA Says Sabadell Offer Remains in Effect

11. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Announced TSB Sale on July 1

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Võrdlus sarnastega

Hinnamuutus

Pharming Group NV Prognoos

Hinnasiht

By TipRanks

69.59% tõus

12 kuu keskmine prognoos

Keskmine 1.73 EUR  69.59%

Kõrge 2.456 EUR

Madal 1.002 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Pharming Group NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.